Systematic review of lung function and COPD with peripheral blood DNA methylation in population based studies by Machin, Matthew et al.
RESEARCH ARTICLE Open Access
Systematic review of lung function and
COPD with peripheral blood DNA
methylation in population based studies
Matthew Machin1†, André F. S. Amaral2,3*†, Matthias Wielscher3,4, Faisal I. Rezwan5, Medea Imboden6,7,
Marjo-Riitta Jarvelin3,4, Ian M. Adcock8, Nicole Probst-Hensch6,7, John W. Holloway5, Deborah L. Jarvis2,3
and on behalf of the ALEC study
Abstract
Background: Epigenetic variations in peripheral blood have potential as biomarkers for disease. This systematic
review assesses the association of lung function and chronic obstructive pulmonary disease (COPD) with DNA
methylation profiles in peripheral blood from population-based studies.
Methods: Online databases Medline, Embase, and Web of Science were searched. Google Scholar was searched
to identify grey literature. After removing duplicate articles, 1155 articles were independently screened by two
investigators. Peer reviewed reports on population-based studies that examined peripheral blood DNA methylation
in participants with measured lung function (FEV1, FEV1/FVC ratio) or known COPD status were selected for full-text
review. Six articles were suitable for inclusion. Information regarding study characteristics, designs, methodologies
and conclusions was extracted. A narrative synthesis was performed based on published results.
Results: Three of the six articles assessed the association of COPD with DNA methylation, and two of these also
included associations with lung function. Overall, five reports examined the association of lung function with DNA
methylation profiles. Five of the six articles reported ‘significant’ results. However, no consistent CpG sites were
identified across studies for COPD status or lung function values.
Conclusions: DNA methylation patterns in peripheral blood from individuals with reduced lung function or COPD
may be different to those in people with normal lung function. However, this systematic review did not find any
consistent associations of lung function or COPD with differentially methylated CpG sites. Large studies with a
longitudinal design to address reverse causality may prove a more fruitful area of research.
Trial registration: PROSPERO 2016: CRD42016037352.
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Background
Epigenetics is the regulation of gene expression which is
independent of the underlying DNA sequence, and is
instead brought about by modifications to histones,
changes in chromatin structure, microRNAs, non-
coding RNAs, and DNA methylation. DNA methylation
is fundamental for normal development and growth—re-
sponsible for imprinting of genes, inactivation of the X
chromosome and cell differentiation [1, 2]. In humans,
the majority of DNA methylation comprises the addition
of a methyl group to cytosine bases within cytosine-
guanine (CpG) DNA sequences [3]. These CpG base-
pairs are concentrated in relatively high densities in
areas known as CpG islands (CGIs) [4, 5]. DNA methy-
lation acts to reduce the activity of transposons, such as
Alu repeats, and thus contributes to genomic stability.
The interaction between DNA methylation and gene
expression is complex. However, it has been long
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theorised that DNA methylation in CGIs achieves gene
repression by preventing transcription factors from bind-
ing to promoter regions and by influencing local chro-
matin remodelling [6].
The use of DNA methylation profiles in peripheral
blood as a biomarker for risk of disease, risk of disease
progression, response to therapy and as a biomarker of
exposure to environmental insults that may influence
disease is an attractive concept as it could be translated
into clinical practice with relative ease. Recent advances
in microarray-techniques have meant that epigenome-
wide association studies (EWAS) are possible, although
the cost of these arrays remains high, limiting applica-
tion to all relevant studies.
Chronic obstructive pulmonary disease (COPD) is esti-
mated to affect 334 million people worldwide [7, 8] with
a global prevalence of 11.7%. It ranks 9th in the all-cause
global disability-adjusted life-years lost. The main risk
factors for COPD are age and cigarette smoking [9–13],
but a history of tuberculosis [14], and perhaps exposure
to biomass [15] is also important in low and middle in-
come countries. Variation in methylation in response to
smoking has been reported in several CGIs [16], which
may reverse with smoking cessation [17], but methyla-
tion markers for COPD and lung function have only
been explored in a few studies.
This systematic review examines the association of
COPD and lung function with global, epigenome-wide,
and locus-specific DNA methylation in peripheral blood
from population-based studies.
Methods
The protocol was registered with PROSPERO (CRD4201
6037352), and methods and reporting followed the
PRISMA guidelines [18].
Search strategy
Searches comprising of 92 terms were applied to Medline,
Embase and Web of Science (WoS) (see Additional file 1:
Table S1) on 10 March 2016. Search terms consisted of
the Medical Subject Headings (MeSH) for epigenetics,
DNA methylation, COPD, cigarette smoke and lung func-
tion, in addition to other relevant keywords (e.g. hyperme-
thylation) inputted as free text. Searches relating to lung
function, COPD and cigarette exposure were carried out
and combined with the “OR” Boolean operator. Searches
relating to epigenetics, DNA methylation and global
methylation were performed and again combined with the
“OR” Boolean operator. The two searches were then com-
bined using the “AND” Boolean operator to ensure that
only studies regarding both DNA methylation and COPD
or lung function were retrieved.
Searches for articles on Medline (MEDLINE In-Process
& Other Non-Indexed Citations and Ovid MEDLINE)
and Embase (Embase Classic + Embase) were based on
“Title” and “Abstract”. The WoS platform was used to
search for “Title” of articles in its Core Collection. Simpli-
fied searches consisting of topic headings for COPD, lung
function and DNA methylation were carried out in
Google Scholar to identify grey literature (i.e. published in
non-commercial form or that falls outside the mainstream
of journal and monograph publications).
Duplicates were identified and removed.
Study inclusion
Titles and Abstracts of articles were screened by two
authors (DLJ and MM) against the predefined inclusion
criteria (Table 1) to identify articles for full-text review.
Only articles assessing the association of lung function
and COPD with DNA methylation were included for
full-text review. Independent full-text reviews were per-
formed on potentially relevant studies. The reference list
of all included studies was screened to identify further
studies, and citations published before the date of the
main search (identified through WoS Citation Indexing
tool) were examined. Articles without an abstract in
English were excluded.
Study eligibility
Articles selected for inclusion had participants with lung
function measures or COPD status ascertained. COPD
patients are at increased risk of lung cancer [19], but
studies of COPD and lung function in lung cancer pa-
tients were excluded, as DNA methylation patterns may
be influenced by lung cancer [20]. Conference abstracts
were excluded. A hierarchy of exclusion was designed to
categorise reasons for article exclusion during screening
of titles and abstracts, but there were discrepancies in
the categorisation of the reasons for exclusion of studies
between investigators (most excluded articles had mul-
tiple reasons for exclusion). We did not attempt to re-
solve these discrepancies. However, studies which either
investigator identified for full-text review were discussed,
Table 1 Inclusion criteria for studies
Criteria
1 Study included COPD patients as a comparator group or a
population defined by lung function
2 Participants must be free of malignancies
3 Articles must be original research and have been published as a full-
text in a peer-reviewed journal
4 Studies must have been carried out in humans (exclusion of in vivo
and in vitro study designs)
5 Studies must assess relative levels of DNA methylation
6 Analysis of DNA methylation must have been in peripheral blood
7 Abstracts must be available in English.
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and studies were only included if both investigators
agreed they were suitable for inclusion.
Data extraction
Study identification (title, author and PubMed ID), study
design (study group, control group, setting, recruitment
and demographics including smoking history and lung
function), methodologies (cell type, method of DNA
methylation measurement, coverage, statistical analysis,
correction methods), results (DNA methylation sites, β-
values) and conclusions were extracted into a standar-
dised template in Microsoft Excel 2013.
Quality assessment
All studies were observational, had different designs,
and different methodologies. The validity and bias of
each study were assessed in regards to study size,
study design, participant selection, adjustment for
confounders, laboratory quality control, and validity
of conclusions.
Justification of narrative
Quantitative analysis was not performed. Studies were
heterogeneous, and tested and reported effect estimates
for different CpG sites. A narrative synthesis was per-
formed to summarise the included articles.
Results
Literature search
Searches of electronic databases identified 2242 articles
(Medline: 809, Embase: 1267, and WoS: 166). Searches
using Google Scholar identified 111 articles resulting in
a total of 2353 potential articles (Fig. 1).
Removal of duplicates (n = 1198) left 1155 articles for
title and abstract screening. This step excluded 1139 ar-
ticles, leaving 16 articles for full-text review. Having read
the full articles, six studies were considered as appropri-
ate for systematic review.
Study approaches
Three studies [21–23] adopted an agnostic approach per-
forming EWAS. Two studies [24, 25] used a candidate-
Fig. 1 The PRISMA flow-diagram illustrating the study selection process
Machin et al. BMC Pulmonary Medicine  (2017) 17:54 Page 3 of 10
loci approach measuring DNA methylation at pre-
determined CpG sites. One study [26] assessed global
methylation across repeat elements Alu and LINE-1.
Three articles [23, 24, 26] compared DNA methyla-
tion patterns of COPD patients with healthy controls.
Five studies [21–23, 25, 26] evaluated the association
of lung function with DNA methylation and, of these,
two (Qiu et al. and Lange et al.) also reported associ-
ations for COPD.
Underlying epidemiological designs were different. Qiu
et al. [23] performed cross-sectional analyses on two
family-based cohorts using the International COPD
Genetics Network (ICGN) as the discovery cohort and
the Boston Early Onset COPD Study (EOCOPD) as the
replicative cohort. Four reports were based on cross-
sectional analyses within cohort studies [21, 22, 25, 26].
Wielscher et al. [24] adopted a unique approach testing
candidate CpG sites that had been identified from
EWAS in lung tissue biopsies from COPD patients. The
Normative Ageing Study cohort was the basis of two of
the included studies [25, 26], both of which carried out
cross-sectional analysis.
Study characteristics
Tables 2 and 3 provide further details on studies and
participants of the included articles. Articles were
published from 2011 to 2015, and were based in the UK
[21, 22], Austria [24] and USA [23, 25, 26]. The Lothian
Birth Cohort 1936 [21] is the study of those born in
Scotland in 1936 and continued to live in the Lothian
area between 2004 and 2007 [27]. The Twins UK cohort
[22] is the follow-up of adult twins (mainly, but not ex-
clusively, female) recruited through media campaigns
from the early 1990s [28]. The Normative Ageing Study
[25, 26] is the follow-up of American male veterans of
World War II and the Korean War. The ICGN and
EOCOPD cohorts [23] comprise the follow up of pa-
tients with COPD and their families, with cases largely
recruited from surgical units and pulmonary clinics.
Wielscher et al. selected patients from the Medical
University of Vienna between the years 2008–2012
[24].th=tlb=
Number of participants included in the reports ranged
from 172 (Bell et al.) to 1458 (Qiu et al.). Marioni et al.
also had a relatively large population (n = 1091) with
other reports consisting of lower population numbers.
The Lothian Birth Cohort 1936 cohort and the Norma-
tive Ageing Study were older than participants in other
studies. COPD participants in the EOCOPD cohort
(47.5 ± 7.1) were younger due to selection criteria (co-
hort selected for age <53).
There were broadly equal numbers of men and women
in the ICGN, EOCOPD and Lothian Birth Cohort 1936
(45.6 female, 64 female and 50.4% female respectively)
and a lower proportion in Wielscher et al. The Twins
UK cohort used by Bell et al. was based entirely on
women, whereas the Normative Aging Study was en-
tirely male.
Definitions of COPD differed across studies.
Previous cigarette exposure, assessed as pack-years,
varied widely across individuals and across studies.
Reported means and standard deviations of pack-year
histories from ICGN, EOCOPD and Normative Ageing
Study imply highly skewed distributions. Information on
previous smoke exposure was not reported for three of
the studies [21, 22, 24].
Forced expiratory volume in 1 s (FEV1) was reported
in four studies [21, 22, 25, 26]. Mean FEV1 values were
similar across studies.
Study methods
Tables 4 and 5 provide information on the laboratory
methods for each report. Three [21–23] utilised bisulfite
microarrays in EWAS. Two of these reports [22, 23]
used the Illumina Infinium HumanMethylation27 Bead-
Chip and one [21] used the Illumina Infinium Human-
Methylation450 BeadChip.
The two studies with a candidate-loci approach per-
formed either bisulfite conversion, followed by polymer-
ase chain reaction (PCR) and pyrosequencing [25], or
methylation-sensitive restriction enzymes (MSRE) and
quantitative polymerase chain reaction (qPCR) [24]. Bi-
sulfite conversion followed by PCR and pyrosequencing
was used to measure Alu and LINE-1 methylation [26].
EWAS quality control
All three EWAS [21–23] used different quality control
measures. These involved the use of duplicate samples,
sex prediction, the removal of low-quality samples due to
inadequate hybridisation, bisulfite conversion and staining
signal, and exclusion of probes with a low call rate. Cor-
rection for potential batch effects was attempted in all
EWAS by including in the regression model batch-related
variables, which were either defined a priori [21, 23] or
identified through principal component analysis [22]. The
use of ComBat or other correction programs for batch ef-
fects were not reported.
Candidate-loci and global methylation quality control
Two studies [25, 26] reported performing bisulfite conver-
sion validation. However, no information regarding sam-
ples excluded due to insufficient bisulfite conversion was
stated. To ensure primer specificity in qPCR, Wielscher et
al. performed melting temperature assessments. Samples
were processed in triplicate and then averaged in two
studies [25, 26]. Wielscher et al. used a subset of 16 dupli-
cates to assess technical accuracy [24].
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Biological sample
Five studies [21–23, 25, 26] measured DNA methylation in
leukocytes and one study [24] assessed DNA methylation
in serum (cell-free DNA). Four studies [21, 22, 25, 26]
reported adjustment for cell type in the processing of the
data. Qiu et al. and Wielscher et al. did not report adjust-
ment for cell type, and Wielscher et al. used cell-free DNA
extracted from serum. All other articles adjusting for
differing white cells used relative proportions of the cell
types, which were directly measured.
Association of DNA methylation and COPD
All three studies assessing DNA methylation with COPD
status reported associations.
Qiu et al. reported that COPD was associated with
3565 differentially methylated sites in the ICGN discov-
ery cohort (FDR-corrected p-value < 0.05) when analyses
were conducted without adjustment for confounders
(age, sex, smoking status, pack-years, and batch effects).
Of note, CpG site cg02181506 in the SERPINA1 gene on
chromosome 14 was top ranked in unadjusted analyses
(hypomethylation associated with COPD) (p-value =
7.3 × 10−22), second ranked in the adjusted analysis
(FDR-corrected p-value = 3.4 × 10−10), and replicated in
the EOCOPD cohort (p-value = 5.1 × 10−4) in the un-
adjusted analysis. Between both cohorts there were 349
CpG sites associated with all three phenotypes: COPD,
FEV1 and FEV1/FVC values (FDR-corrected p-value <
0.05), one of these being another SERPINA1 CpG site
(cg24621042).
Wielscher et al. reported four significant (FDR-corrected
p-value < 0.05) CpG sites - cg05979020 (HOXD10),
cg05964935 (N/A), cg05769349 (TBX5) and cg10384245
(ADCYAP1) - from their COPD case-control comparison.
All four were hypermethylated in the presence of COPD
and none were included in any published tabulations of
results from the Qiu et al. report.
Lange et al. reported that hypermethylation of Alu
elements was significantly associated (unadjusted p-
value = 0.046) with a lower odds ratio of COPD (OR
0.80: 0.64–0.99). No significant association with LINE-1
methylation was observed.
Association of DNA methylation and lung function
Four of the five [22, 23, 25, 26] studies assessing the
association of lung function with DNA methylation
reported significant findings.
Marioni et al. in an EWAS of FEV1 adjusted for age,
sex, height, and smoking, based on the Infinium Human-
Methylation450 BeadChip, in 1092 older adults found no
probes passed the Bonferroni significance threshold (1.1 ×
10−7), but 2 sites reached p < 1 × 10−5 (Chromosome 2,
Table 3 Characteristics of participants in reviewed studies
Study n n COPD
patients
n controls Age (mean ±
SD)
FEV1 (L)
(mean ± SD)
FEV1/FVC%
(mean ± SD)
Pack-years
(mean ± SD)
%Current
smoker
%
Female
Qiu et al.[23] 1085 620 325 57.3 ± 8.1 N/A 54.4 ± 19.8 41.7 ± 26.2 36.5 45.6
369 181 109 47.5 ± 7.1 N/A 54.3 ± 21.1 28.7 ± 23.6 27.9 64
Bell et al. [22] 172 N/A N/A 57.2 ± 8.2 2.46 ± 0.46 N/A N/A 15.1a 100
Lepeule et al. [25] 756 81 + 42b N/A 73.3 ± 6.7 2.50 ± 0.6 N/A 20.5 ± 25.7 4 0
Lange et al. [26] 663 107 N/A 72.7 ± 6.7 2.70 ± 0.64 75 ± 8 30.6 ± 24.8 7 0
Marioni et al. [21] 1091 N/A N/A 69.8 ± 0.78 2.36 ± 0.69 N/A N/A N/A 50.4
Wielscher et al.
[24]
204 42 27 healthy +
34 GOLD grade
0
53.4± 13.4c N/A N/A N/A N/A 23.2d
aValue from entire Twins UK cohort obtained from reference [28]
bn COPD patients: 81 chronic bronchitis & 42 emphysema
cInformation provided by the author Wielscher (not available in the original text)
dInformation provided by the author Wielscher (not available in the original text)
Table 4 Laboratory methods of studies performing Epigenome-Wide Association Studies
Study Year Sample analysed Methylation Analysis Technique Coverage Level Blood cell-type Correction
Qiu et al. [23] 2011 Leukocytes Bisulfite Microarrays Infinium HumanMethylation27
BeadChip
No
Bell et al. [22] 2012 Leukocytes Bisulfite Microarrays Infinium HumanMethylation27
BeadChip
Yes (proportion of lymphocytes)
Marioni et al. [21] 2015 Leukocytes Bisulfite Microarrays Infinium HumanMethylation450
BeadChip
Yes (proportion of leukocytesa)
abasophils, monocytes, lymphocytes, eosinophils and neutrophils
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cg14961391, origin recognition complex, subunit 4;
Chromosome 14, cg23710823, POTE ankyrin domain
family, member M). None were included in any published
tabulations of results from Qiu et al. or Bell et al.
Qiu et al. reported significant associations of lung
function measures (FEV1 and FEV1/FVC), publishing ef-
fect estimates for the top 100 (by p-value) which were
associated with both measures (e.g. FXYD1-cg27461196;
SERPINA1-cg02181506). All, except one, of the top CpG
sites (cg21969640) from Qiu et al. were also present in
the more recent Infinium HumanMethylation450 Bead-
Chip, which was used by Marioni et al. but were not
found to be significant in this other study.
Bell at al. identified one significant (Bonferroni cor-
rected p-value < 0.05) CpG site associated with FEV1-
cg16463460 in the WT1 gene (p = 5.31 × 10−7; Beta-value
= −0.035). This CpG site, which was present in both Infi-
nium HumanMethylation BeadChips, was not reported as
significant in the other included studies.
Lepeule et al. examining associations of methylation in
the promoter region of nine genes, involved in inflam-
mation and oxidative stress, with FEV1, FVC, FEV1/
FVC and maximum mid-expiratory flow (MMEF) ob-
served decreased methylation in CRAT, F3, iNOS, OGG1
and TLR2 to be associated with worse lung function.
They also reported that some of these associations (for
example, that of FEV1 with methylation of TLR2) may
alter with age. Hypomethylation of IFNγ and IL6 was as-
sociated with better lung function. Although Lepeule et
al. had lung function and methylation data at two time
points (388 men, average 4 years 7 months apart) au-
thors reported changes in lung function were too small
to consider examining longitudinal change in lung func-
tion with longitudinal change in methylation. The sites
tested by Lepeule et al. could not be compared to those
tested in the other studies.
Discussion
To our knowledge, this is the only systematic review
examining associations of lung function, or COPD, with
DNA methylation profiles in peripheral blood. This re-
view assessed 1115 unique articles, subsequently includ-
ing six. DNA methylation profiles in those with reduced
lung function or COPD may differ to that of a person
with normal healthy lung function, but we found no
consistent findings within the published data. While our
manuscript was under review, Busch et al. published
findings from a small sample (n = 362) of African-
American smokers from the PA-SCOPE study, who were
recruited during inpatient hospitalisation for acute ex-
acerbation of COPD [29]. One of their 12 hits (FDR
< 10%) for COPD was reported by Qiu et al. in the
ICGN cohort (FXYD1-cg27461196) with an FDR-
corrected p-value of 0.08 and none of the others had
been reported previously.
The lack of consistency within the published data
could be related to the considerable heterogeneity across
the studies in several aspects of study design, laboratory
methods and statistical analyses. All studies performed
cross-sectional analysis and reported associations that
are subject to reverse causality. COPD or reduced lung
function could be the cause of the altered DNA methyla-
tion profiles, rather than the result. None of the studies
provided information on whether the samples had been
collected during an exacerbation episode or not (except
for Busch et al., whose participants were hospitalised for a
COPD exacerbation). However, most were population-
based studies with collection of samples either at baseline
or at follow-up for all participants, making it unlikely that
samples were collected during an exacerbation episode.
Wielscher et al. who used COPD patient samples collected
from a medical university may be an exception, but we
could not check it further. The adjustment for con-
founders varied considerably across studies, and although
most adjusted for age and smoking, the way the latter was
treated varied too. Three studies reported and adjusted for
the proportions of smokers and pack-years [23, 25, 26],
one study did not provide information on smoking his-
tory, but adjusted for smoking status [21]. However, two
studies neither provided data on smoking history nor ad-
justed for smoking [22, 24]. The different way in dealing
with smoking history may have contributed to the differ-
ent findings across the studies. While some studies re-
ported the proportions of different races/ethnicities in
their sample [21, 23, 25, 26] and adjusted for these in their
analyses [25, 26], others did not even report it [22, 24].
Table 5 Laboratory methods of studies performing candidate-loci or global methylation studies
Study Year Sample
analysed
Methylation Analysis
Technique
Coverage Level Blood cell-type Correction
Lepeule et al. [25] 2012 Leukocytes PCR and Pyrosequencing 9 candidate genes in pathways of interest:
CRAT, F3, GCR, ICAM, IFNγ, IL6, iNOS, OGG1, TLR2
Yes (proportion of
lymphocytes
and neutrophils)
Lange et al. [26] 2012 Leukocytes PCR and Pyrosequencing Alu and LINE-1 elements: coverage of 15,000
different Alu elements/genome.
Yes (proportion of
lymphocytes)
Wielscher et al. [24] 2015 Serum
(Cell-Free DNA)
MSRE Enrichment and qPCR 63 candidate loci (markers from a 450 K
DNAm of lung tissue from those with COPD)
N/A (cell-free DNA)
Abbreviations: PCR Polymerase chain reaction, qPCR Quantitative polymerase chain reaction, MSRE Methyl sensitive restriction enzyme
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This raises the question of whether the findings of some
of the studies may be affected by genetic and non-genetic
factors specific to the different races/ethnicities, which are
known to influence lung function.
There is currently no standardised, or optimal, proced-
ure for the measurement of DNA methylation, and al-
though apparently rigorous, laboratory quality control for
both EWAS [21–23] and candidate studies varied. There
were different strategies to account for laboratory
methods and to account for cell distribution. Qiu et al. did
not adjust for white cell counts despite reporting DNA
methylation of leukocytes as a whole, and this omission
could lead to confounding by the methylation profiles
from each cell type [30]. Such adjustment may be particu-
larly important in diseases which have a characteristic im-
mune response, such as the neutrophilic inflammation
seen in COPD [31], or common environmental exposures
(e.g. tobacco smoke) that have also been shown to be asso-
ciated with changes in blood cell counts. All three EWAS
corrected for potential batch effects.
Notably, there were also differences in the statistical
approach to adjustment for potential confounders. This
is important as epigenome association studies are sus-
ceptible to confounding (i.e. observed associations with
one outcome may be due to true associations with
another factor), and may be of particular relevance to
COPD, which is strongly related to smoking and is asso-
ciated with multiple morbidities. While the association
of an outcome with DNA methylation can be con-
founded by several exposures, DNA methylation may be
the result of exposures that are on the causal pathway to
disease (i.e. exposures not acting as confounders) and a
careful approach to adjustment for such exposures is
needed - this should depend on the underlying scientific
question that is being considered.
No power calculations for identification of epigenome
wide associations were reported, but attempts were
made by many to adjust for multiple testing. Lepeule et
al. (using a candidate-loci approach) failed to correct for
multiple testing. Except for Qiu et al., who attempted to
replicate their findings from ICGN within EOCOPD, all
other reports were based on single studies.
This systematic review was carried out with a predefined
protocol registered with PROSPERO and in accordance
with the PRISMA checklist. Articles were identified using
three large online databases using a comprehensive selec-
tion of search terms (consisting of both MeSH and free
text) with additional simplified searches to identify grey
literature. To make the searches as sensitive as possible,
no limits were imposed on the search regarding date of
publication, language, or article type.
Screening of articles, full-text review and data extrac-
tion was carried out by two investigators independently,
with each providing reasons for exclusion for each
article (see Additional files 2: Table S2). Limitations of
this review were that: 1) conference abstracts, which
may have contained potentially relevant emerging data,
were excluded. However, these usually do not reflect the
final conclusion of the study, often require corrections
prior to publication and the amount of information on
the methods is limited; 2) abstracts of articles had to be
available in English; and 3) we only searched online
databases from the USA and Europe.
Conclusion
There were no consistent findings across the identified
studies examining the association of lung function or
COPD with peripheral blood DNA methylation, possibly
due to the heterogeneity of methods used, and even with
access to full sets of unpublished results we would hesi-
tate to combine results from these studies because of the
different laboratory quantification, quality control and
analytical methods used. Reports were based on cross-
sectional analyses of DNA methylation and lung func-
tion/COPD (even though participants were taking part
in cohort studies) and methylation patterns could be the
cause of, or a result of, altered lung function. Some re-
ported associations might have been related to smoking
rather than to disease or lung function per se. Further-
more, COPD patients may also suffer from other condi-
tions, or take drug therapies, which may be associated
with differential DNA methylation.
Future longitudinal studies, with serial measurements of
DNA methylation at yearly intervals, are required to assess
the temporal sequence of disease onset and peripheral
blood methylation. Harmonization of methods, and estab-
lished guidelines for quality control and processing of
DNA methylation data would facilitate meta-analysis of
epigenome association studies. There is some evidence of
associations with highly biologically plausible areas (e.g.
SERPINA1), and targeted analyses to investigate these
further are warranted.
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